海峡药学
海峽藥學
해협약학
STRAIT PHARMACEUTICAL JOURNAL
2014年
11期
122-126
,共5页
洪小凤%许新容%林晶%CHEN Xiao-xiao
洪小鳳%許新容%林晶%CHEN Xiao-xiao
홍소봉%허신용%림정%CHEN Xiao-xiao
红花黄色素注射液%稳定型心绞痛%Meta分析%随机对照试验
紅花黃色素註射液%穩定型心絞痛%Meta分析%隨機對照試驗
홍화황색소주사액%은정형심교통%Meta분석%수궤대조시험
Safflower Yellow Injection%Stable Angina Pectoris%meta-analysis%Randomized controlled trials
目的:系统评价红花黄色素治疗稳定型心绞痛的临床疗效和安全性。方法通过全面检索与红花黄色素治疗稳定型心绞痛相关的随机对照临床试验研究文献,运用Cochrane图书馆系统评价方法,对纳入的文献进行质量评价及Meta分析。结果13个随机对照试验纳入系统评价,包含了3024例患者。 Meta分析结果显示:红花黄色素注射液组对心绞痛症状总体疗效显著优于对照组,差异有统计学意义( OR=2.69,95% CI(1.95,3.70),P <0.01);对中医症候疗效(OR =2.73,95% CI(2.20,3.38),P <0.01)及心电图情况的改善方面(OR =1.72,95% CI (1.31,2.25),P<0.01),试验组亦显著优于对照组。结论红花黄色素注射液治疗稳定型心绞痛在临床症状、中医症候、心电图改善方面疗效确切,而不良反应与对照组比较没有明显差别,安全性较好。但受纳入文献的质量限制及可能存在的发表性偏倚,本结论仍需更多多中心、大样本的随机双盲对照实验进一步证实。
目的:繫統評價紅花黃色素治療穩定型心絞痛的臨床療效和安全性。方法通過全麵檢索與紅花黃色素治療穩定型心絞痛相關的隨機對照臨床試驗研究文獻,運用Cochrane圖書館繫統評價方法,對納入的文獻進行質量評價及Meta分析。結果13箇隨機對照試驗納入繫統評價,包含瞭3024例患者。 Meta分析結果顯示:紅花黃色素註射液組對心絞痛癥狀總體療效顯著優于對照組,差異有統計學意義( OR=2.69,95% CI(1.95,3.70),P <0.01);對中醫癥候療效(OR =2.73,95% CI(2.20,3.38),P <0.01)及心電圖情況的改善方麵(OR =1.72,95% CI (1.31,2.25),P<0.01),試驗組亦顯著優于對照組。結論紅花黃色素註射液治療穩定型心絞痛在臨床癥狀、中醫癥候、心電圖改善方麵療效確切,而不良反應與對照組比較沒有明顯差彆,安全性較好。但受納入文獻的質量限製及可能存在的髮錶性偏倚,本結論仍需更多多中心、大樣本的隨機雙盲對照實驗進一步證實。
목적:계통평개홍화황색소치료은정형심교통적림상료효화안전성。방법통과전면검색여홍화황색소치료은정형심교통상관적수궤대조림상시험연구문헌,운용Cochrane도서관계통평개방법,대납입적문헌진행질량평개급Meta분석。결과13개수궤대조시험납입계통평개,포함료3024례환자。 Meta분석결과현시:홍화황색소주사액조대심교통증상총체료효현저우우대조조,차이유통계학의의( OR=2.69,95% CI(1.95,3.70),P <0.01);대중의증후료효(OR =2.73,95% CI(2.20,3.38),P <0.01)급심전도정황적개선방면(OR =1.72,95% CI (1.31,2.25),P<0.01),시험조역현저우우대조조。결론홍화황색소주사액치료은정형심교통재림상증상、중의증후、심전도개선방면료효학절,이불량반응여대조조비교몰유명현차별,안전성교호。단수납입문헌적질량한제급가능존재적발표성편의,본결론잉수경다다중심、대양본적수궤쌍맹대조실험진일보증실。
OBJECTIVE To evaluate the efficacy and safety of Safflower Yellow Injection ( SYI ) in the treat-ment of Stable Angina Pectoris( SAP).METHODS Randomized controlled trials( RCTs) on the efficacy and safety of SYI in treating patients with SAP were retrieved in the following databases as CNKI,WanFang Data,Pubmed et al.The literature which met the inclusion and exclusion criteria were selected,data were extracted,the quality was e-valuated,and meta-analysis was performed by using RevMan 5.0 software.RESULTS A total of 13 RCTs involving 2612 patients were included.The meta-analysis showed that,compared with the control group,SYI was significantly superior in the following 3 aspects:the efficacy on Angina(OR=2.69,95% CI(1.95,3.70),P<0.01),the total effect on TCM Symptoms(OR=2.73,95%CI(2.20,3.38),P<0.01),and the efficacy on ECG(OR=1.72,95%CI(1.31,2.25),P<0.01).CONCLUSION Based on current studies,SYI is superior to other medicines in the control group for SAP at present,and it has no significant difference in side effects compared with the control group, so it is regarded as an effective and safe drug.For the quality restrictions and possible publication bias of the included studies,this conclusion needs to be confirmed by more high quality,large sample,muiti-center,double blind RCTs.